EUR 309.30 For Business Accounts Only

Pharmaceuticals in Japan

Summary
Pharmaceuticals in Japan industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Japan
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Japan
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Japan pharmaceuticals market with five year forecasts

Synopsis
Essential resource for top-line data and analysis covering the Japan pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buys

- What was the size of the Japan pharmaceuticals market by value in 2016?
- What will be the size of the Japan pharmaceuticals market in 2021?
- What factors are affecting the strength of competition in the Japan pharmaceuticals market?
- How has the market performed over the last five years?
- Who are the top competitiors in Japan's pharmaceuticals market?

Key Highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2016 annual average exchange rates.
- The Japanese pharmaceuticals market had total revenues of $70.0bn in 2016, representing a compound annual rate of change (CARC) of -0.2% between 2012 and 2016.
- In Japan, every citizen is required to participate in the National Health Insurance (NHI) scheme and the majority of health care spending is publically funded through this and other government funds.
- In April 2016, a new Health Technology Assessment (HTA) system was introduced, as a pilot program focused on the re-pricing of seven drugs and six medical devices that had been launched in previous years.